Reported 1 day ago
Soleno Therapeutics, Inc. (NASDAQ:SLNO) is considered one of the best-performing healthcare stocks, ranking third in a recent analysis. The company specializes in treatments for rare diseases, notably Prader-Willi Syndrome, and its latest product, VYKAT XR, has received FDA approval. Recent developments include a favorable executive order from President Trump aiming to reform drug price negotiations, potentially benefiting the pharmaceutical sector. Despite Soleno's promising performance with a year-to-date increase of 70.81%, analysts suggest that some AI stocks might present even higher growth opportunities.
Source: YAHOO